Biotage (BIOT.ST) Stock Analysis & AI Equity Report
Biotage (BIOT.ST) overview
Biotage (BIOT.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, Biotage reported revenue of SEK 2,056m and operating profit of SEK 383m; the year-end share price was 160.80 SEK and market capitalisation was SEK 12,869m. Biotage is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Biotage's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-05. Data will be refreshed during report generation.
About Biotage
Biotage AB develops and sells separation and purification technologies for laboratories in drug discovery, development, and analytical testing. Its portfolio includes automated sample preparation systems, flash and peptide purification tools, biomolecule purification products, and related consumables and services. The company also serves applications in environmental, forensic, food, and other testing workflows.
Generate the Biotage report
Biotage is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Biotage and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.